Skip To Content
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Before it's here, it's on the Bloomberg Terminal.
Learn More
ALXN:USNASDAQ GS

Alexion Pharmaceuticals Inc

COMPANY INFO
110.85USD
+1.81+1.66%
Market Closed
As of 08/16/2019 EDT
Open
110.27
Prev Close
109.04
Volume
1,254,773
Market Cap
24.856B
Day Range
109.57111.41
52 Week Range
92.56141.86
1D1M1Y5Y
View Full Chart
Market Closed
As of 08/16/2019 EDT
1D1M1Y5Y
View Full Chart
markets
Walmart Jumps Most in a Year on Strong 2Q Sales
Before it's here, it's on the Bloomberg Terminal.
Learn More
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.

Key Statistics

P/E Ratio13.70
Bloomberg (BEst) P/E Ratio10.9018
Bloomberg (BEst) PEG Ratio0.7035
Shares Outstanding224.23M
Price to Book Ratio2.4453
Price to Sales Ratio5.5080
1 Year Return-4.44%
30 Day Avg Volume2,019,823
EPS8.09
Bloomberg (BEst) EPS Curr Yr9.8890
Dividend--
Last Dividend Reported--
Earnings Announcement for Period Ending Q3/2019:10/24/2019

Compare
1-Day Performance

0+2%
0+2%
Equity
ALXN:US
+1.66%
Sponsored By

About Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
Address
121 Seaport Blvd Boston, MA 02210 United States
Phone
1-475-230-2596
Website
www.alexion.com

Income Statement

Quarterly
Annual
;
Q2 2019 (Millions USD)
  • Revenue
    1,203.30
  • Net Income
    459.80
  • Profit Margin
    38.21%

Balance Sheet

Quarterly
Annual
;
Q2 2019 (Millions USD)
  • Total Assets
    14,567.70
  • Total Liabilities
    4,404.20
  • Debt to Assets
    19.43%

Cash Flow

Quarterly
Annual
Q2 2019 (Millions USD)
  • Operating
    538.40
  • Investing
    -41.00
  • Financing
    -59.00